8-K
CONMED Corp (CNMD)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 28, 2026
CONMED CORPORATION
(Exact name of registrant as specified in its charter)
| Delaware | 001-39218 | 16-0977505 |
|---|---|---|
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer<br>Identification No.) |
| 11311 Concept Blvd<br><br>Largo, FL | 33773 | |
| --- | --- | |
| (Address of principal executive offices) | (Zip code) |
(727) 392-6464
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Rule 12(b) of the Act
| Title of each class | Trading Symbol | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.01 par value | CNMD | NYSE |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition
On January 28, 2026, CONMED Corporation issued a press release announcing financial results for the fourth quarter ended December 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K that is furnished under “Item 2.02. Results of Operations and Financial Condition” and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibits are included herewith:
| Exhibit No. | Description of Exhibit |
|---|---|
| 99.1 | Press release datedJanuary 28, 2026, issued by CONMED Corporation. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document). |
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: January 28, 2026 | CONMED CORPORATION |
|---|---|
| (Registrant) | |
| By: | /s/ Todd W. Garner |
| --- | --- |
| Name: | Todd W. Garner |
| Title: | Executive Vice President, Finance & Chief Financial Officer |
Document
NEWS RELEASE
| CONTACT: |
|---|
| CONMED Corporation |
| Pat Beyer |
| Chief Executive Officer |
| PatBeyer@conmed.com |
CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results
Largo, Florida, January 28, 2026 – CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025.
Fourth Quarter 2025 Highlights
•Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency.
•Domestic revenue increased 1.4% year-over-year.
•International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency.
•Diluted net earnings per share (GAAP) were $0.54, compared to diluted net earnings per share (GAAP) of $1.08 in the fourth quarter of 2024.
•Adjusted diluted net earnings per share(1) were $1.43, compared to adjusted diluted net earnings per share of $1.34 in the fourth quarter of 2024.
Full-Year 2025 Highlights
•Sales of $1,374.7 million increased 5.2% year-over-year as reported and 5.1% in constant currency.
•Domestic revenue increased 3.5% year-over-year.
•International revenue increased 7.4% year-over-year as reported and 7.1% in constant currency.
•Diluted net earnings per share (GAAP) were $1.51, compared to diluted net earnings per share (GAAP) of $4.25 in 2024.
•Adjusted diluted net earnings per share(1) were $4.59, compared to adjusted diluted net earnings per share of $4.17 in 2024.
“Our fourth quarter results reflect steady execution across the business as well as progress on our operational initiatives,” said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “As we begin 2026 with a sharpened strategic focus, we remain disciplined in our operating approach and confident in the long‑term potential of our key growth drivers in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.”
2026 Outlook
The Company expects full-year 2026 reported revenue between $1.345 billion and $1.375 billion. This represents year over year organic constant currency growth of approximately 4.5% to 6% over 2025 revenue when excluding sales of gastroenterology products from both years, and approximately 0 to 50 basis points of currency tailwind.
The Company expects full-year 2026 adjusted diluted net earnings per share(2) in the range of $4.30 to $4.45. This includes a currency tailwind of approximately $0.10.
Supplemental Financial Disclosures
(1) A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.
(2) Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.
Conference Call
The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its fourth quarter and full-year 2025 results.
To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.
This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
| Consolidated Condensed Statements of Income | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands except per share amounts, unaudited) | ||||||||||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||||||||||
| December 31, | December 31, | |||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||
| Net sales | $ | 373,198 | $ | 345,944 | $ | 1,374,724 | $ | 1,307,015 | ||||||||||||||||
| Cost of sales | 154,912 | 147,600 | 624,249 | 573,983 | ||||||||||||||||||||
| Gross profit | 218,286 | 198,344 | 750,475 | 733,032 | ||||||||||||||||||||
| % of sales | 58.5 | % | 57.3 | % | 54.6 | % | 56.1 | % | ||||||||||||||||
| Selling & administrative expense | 166,764 | 132,669 | 591,969 | 478,280 | ||||||||||||||||||||
| Research & development expense | 14,899 | 13,176 | 55,884 | 54,426 | ||||||||||||||||||||
| Income from operations | 36,623 | 52,499 | 102,622 | 200,326 | ||||||||||||||||||||
| % of sales | 9.8 | % | 15.2 | % | 7.5 | % | 15.3 | % | ||||||||||||||||
| Interest expense | 7,370 | 8,857 | 31,087 | 37,297 | ||||||||||||||||||||
| Other expense | - | - | 418 | - | ||||||||||||||||||||
| Income before income taxes | 29,253 | 43,642 | 71,117 | 163,029 | ||||||||||||||||||||
| Provision for income taxes | 12,514 | 9,888 | 24,062 | 30,606 | ||||||||||||||||||||
| Net income | $ | 16,739 | $ | 33,754 | $ | 47,055 | $ | 132,423 | ||||||||||||||||
| Basic EPS | $ | 0.54 | $ | 1.09 | $ | 1.52 | $ | 4.29 | ||||||||||||||||
| Diluted EPS | 0.54 | 1.08 | 1.51 | 4.25 | ||||||||||||||||||||
| Basic shares | 30,968 | 30,923 | 31,036 | 30,846 | ||||||||||||||||||||
| Diluted shares | 31,030 | 31,146 | 31,149 | 31,150 | ||||||||||||||||||||
| Sales Summary | ||||||||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||||
| (in millions, unaudited) | ||||||||||||||||||||||||
| Three Months Ended December 31, | ||||||||||||||||||||||||
| % Change | ||||||||||||||||||||||||
| Domestic | International | |||||||||||||||||||||||
| 2025 | 2024 | As Reported | Impact of Foreign Currency | Constant Currency | As Reported | As Reported | Impact of Foreign Currency | Constant Currency | ||||||||||||||||
| Orthopedic Surgery | $ | 157.4 | $ | 139.0 | 13.2 | % | -1.1 | % | 12.1 | % | 6.6 | % | 17.5 | % | -1.8 | % | 15.7 | % | ||||||
| General Surgery | 215.8 | 206.9 | 4.3 | % | -0.5 | % | 3.8 | % | -0.4 | % | 16.3 | % | -1.5 | % | 14.8 | % | ||||||||
| $ | 373.2 | $ | 345.9 | 7.9 | % | -0.8 | % | 7.1 | % | 1.4 | % | 17.0 | % | -1.6 | % | 15.4 | % | |||||||
| Single-use Products | $ | 320.6 | $ | 297.3 | 7.8 | % | -0.7 | % | 7.1 | % | 1.5 | % | 17.6 | % | -1.7 | % | 15.9 | % | ||||||
| Capital Products | 52.6 | 48.6 | 8.2 | % | -0.9 | % | 7.3 | % | 1.4 | % | 14.4 | % | -1.6 | % | 12.8 | % | ||||||||
| $ | 373.2 | $ | 345.9 | 7.9 | % | -0.8 | % | 7.1 | % | 1.4 | % | 17.0 | % | -1.6 | % | 15.4 | % | |||||||
| Domestic | $ | 206.2 | $ | 203.3 | 1.4 | % | 0.0 | % | 1.4 | % | ||||||||||||||
| International | 167.0 | 142.6 | 17.0 | % | -1.6 | % | 15.4 | % | ||||||||||||||||
| $ | 373.2 | $ | 345.9 | 7.9 | % | -0.8 | % | 7.1 | % | |||||||||||||||
| Year Ended December 31, | ||||||||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||||
| % Change | ||||||||||||||||||||||||
| Domestic | International | |||||||||||||||||||||||
| 2025 | 2024 | As Reported | Impact of Foreign Currency | Constant Currency | As Reported | As Reported | Impact of Foreign Currency | Constant Currency | ||||||||||||||||
| Orthopedic Surgery | $ | 574.6 | $ | 544.0 | 5.6 | % | -0.1 | % | 5.5 | % | 2.3 | % | 7.8 | % | -0.2 | % | 7.6 | % | ||||||
| General Surgery | 800.1 | 763.0 | 4.9 | % | -0.2 | % | 4.7 | % | 4.0 | % | 6.9 | % | -0.5 | % | 6.4 | % | ||||||||
| $ | 1,374.7 | $ | 1,307.0 | 5.2 | % | -0.1 | % | 5.1 | % | 3.5 | % | 7.4 | % | -0.3 | % | 7.1 | % | |||||||
| Single-use Products | $ | 1,183.8 | $ | 1,112.1 | 6.4 | % | -0.1 | % | 6.3 | % | 4.0 | % | 9.9 | % | -0.3 | % | 9.6 | % | ||||||
| Capital Products | 190.9 | 194.9 | -2.1 | % | 0.0 | % | -2.1 | % | -0.3 | % | -3.6 | % | -0.2 | % | -3.8 | % | ||||||||
| $ | 1,374.7 | $ | 1,307.0 | 5.2 | % | -0.1 | % | 5.1 | % | 3.5 | % | 7.4 | % | -0.3 | % | 7.1 | % | |||||||
| Domestic | $ | 774.6 | $ | 748.2 | 3.5 | % | 0.0 | % | 3.5 | % | ||||||||||||||
| International | 600.1 | 558.8 | 7.4 | % | -0.3 | % | 7.1 | % | ||||||||||||||||
| $ | 1,374.7 | $ | 1,307.0 | 5.2 | % | -0.1 | % | 5.1 | % | |||||||||||||||
| Reconciliation of Reported Net Income to Adjusted Net Income | ||||||||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (in thousands, except per share amounts, unaudited) | ||||||||||||||||||||||||
| Three Months Ended December 31, 2025 | ||||||||||||||||||||||||
| Gross Profit | Selling & Administrative Expense | Research & Development Expense | Operating Income | Interest Expense | Other Expense | Tax Expense | Effective Tax Rate | Net Income | Diluted EPS | |||||||||||||||
| As reported | $ | 218,286 | $ | 166,764 | $ | 14,899 | $ | 36,623 | $ | 7,370 | $ | - | $ | 12,514 | 42.8 | % | $ | 16,739 | $ | 0.54 | ||||
| % of sales | 58.5 | % | 44.7 | % | 4.0 | % | 9.8 | % | ||||||||||||||||
| Contingent consideration fair value adjustments(1) | - | (19,446) | - | 19,446 | - | - | 278 | 19,168 | ||||||||||||||||
| Product rationalization costs(2) | 2,596 | (2,234) | - | 4,830 | - | - | 69 | 4,761 | ||||||||||||||||
| Operational optimization consulting fees(3) | 188 | (4,469) | - | 4,657 | - | - | 67 | 4,590 | ||||||||||||||||
| EU medical device regulations(4) | - | - | (785) | 785 | - | - | 11 | 774 | ||||||||||||||||
| Legal matters(5) | - | (60) | - | 60 | - | - | 1 | 59 | ||||||||||||||||
| Termination of distribution agreement(6) | (9,866) | - | - | (9,866) | - | - | (141) | (9,725) | ||||||||||||||||
| $ | 211,204 | $ | 140,555 | $ | 14,114 | $ | 56,535 | $ | 7,370 | $ | - | $ | 12,799 | $ | 36,366 | |||||||||
| Adjusted gross profit % | 56.6 | % | ||||||||||||||||||||||
| Amortization(7) | $ | 1,500 | (7,591) | - | 9,091 | (1,539) | - | 2,563 | 8,067 | |||||||||||||||
| As adjusted | $ | 132,964 | $ | 14,114 | $ | 65,626 | $ | 5,831 | $ | - | $ | 15,362 | 25.7 | % | $ | 44,433 | $ | 1.43 | ||||||
| % of sales | 35.6 | % | 3.8 | % | 17.6 | % | ||||||||||||||||||
| Three Months Ended December 31, 2024 | ||||||||||||||||||||||||
| Gross Profit | Selling & Administrative Expense | Research & Development Expense | Operating Income | Interest Expense | Other Expense | Tax Expense | Effective Tax Rate | Net Income | Diluted EPS | |||||||||||||||
| As reported | $ | 198,344 | $ | 132,669 | $ | 13,176 | $ | 52,499 | $ | 8,857 | $ | - | $ | 9,888 | 22.7 | % | $ | 33,754 | $ | 1.08 | ||||
| % of sales | 57.3 | % | 38.3 | % | 3.8 | % | 15.2 | % | ||||||||||||||||
| Contingent consideration fair value adjustments(1) | - | (1,219) | - | 1,219 | - | - | 1,058 | 161 | ||||||||||||||||
| Hurricane impact(8) | 955 | - | - | 955 | - | - | 829 | 126 | ||||||||||||||||
| Lease impairment(9) | - | (606) | - | 606 | - | - | 526 | 80 | ||||||||||||||||
| Legal matters(5) | - | (531) | - | 531 | - | - | 461 | 70 | ||||||||||||||||
| $ | 199,299 | $ | 130,313 | $ | 13,176 | $ | 55,810 | $ | 8,857 | $ | - | $ | 12,762 | $ | 34,191 | |||||||||
| Adjusted gross profit % | 57.6 | % | ||||||||||||||||||||||
| Amortization(7) | $ | 1,500 | (7,162) | - | 8,662 | (1,443) | - | 2,456 | 7,649 | |||||||||||||||
| As adjusted | $ | 123,151 | $ | 13,176 | $ | 64,472 | $ | 7,414 | $ | - | $ | 15,218 | 26.7 | % | $ | 41,840 | $ | 1.34 | ||||||
| % of sales | 35.6 | % | 3.8 | % | 18.6 | % | ||||||||||||||||||
| (1) In 2025 and 2024, the Company recorded expense related to the fair value adjustments of contingent consideration. | ||||||||||||||||||||||||
| --- | ||||||||||||||||||||||||
| (2) In 2025, the Company wrote off inventory, equipment, tooling and patents to cost of goods sold related to the cancellation of planned new product lines and discontinuation of certain catalog numbers as a result of our operational optimization consultation and internal review. In addition, we wrote off the developed technology intangible asset to selling and administrative expense. | ||||||||||||||||||||||||
| (3) In 2025, the Company incurred costs related to the engagement of a consulting firm to evaluate and propose improvements to our manufacturing operations which are included in cost of sales. In addition, we incurred consulting fees and other charges related to operational optimization which are included in selling & administrative expense. | ||||||||||||||||||||||||
| (4) In 2025, the Company incurred costs to comply with the European Union's Medical Device Regulations (MDR). | ||||||||||||||||||||||||
| (5) In 2025 and 2024, the Company incurred costs for third party services pertaining to potential issues with certain royalty payments to design surgeons. | ||||||||||||||||||||||||
| (6) In 2025, the Company incurred income related to the early termination of an agreement granting the Company exclusive distribution rights. | ||||||||||||||||||||||||
| (7) Includes amortization of intangible assets and deferred financing fees. | ||||||||||||||||||||||||
| (8) In 2024, the Company incurred costs due to the impact of Hurricane Milton on our Largo, FL facility. These costs were mainly comprised of emergency pay to employees and plant underutilization due to abnormally low production. | ||||||||||||||||||||||||
| (9) In 2024, the Company recorded lease impairment expense related to a storage facility no longer utilized. | ||||||||||||||||||||||||
| Reconciliation of Reported Net Income to Adjusted Net Income | ||||||||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (in thousands, except per share amounts, unaudited) | ||||||||||||||||||||||||
| Year Ended December 31, 2025 | ||||||||||||||||||||||||
| Gross Profit | Selling & Administrative Expense | Research & Development Expense | Operating Income | Interest Expense | Other Expense | Tax Expense | Effective Tax Rate | Net Income | Diluted EPS | |||||||||||||||
| As reported | $ | 750,475 | $ | 591,969 | $ | 55,884 | $ | 102,622 | $ | 31,087 | $ | 418 | $ | 24,062 | 33.8 | % | $ | 47,055 | $ | 1.51 | ||||
| % of sales | 54.6 | % | 43.1 | % | 4.1 | % | 7.5 | % | ||||||||||||||||
| Operational optimization costs(1) | 12,450 | (12,926) | - | 25,376 | - | - | 4,112 | 21,264 | ||||||||||||||||
| Product rationalization costs(2) | 22,249 | (2,234) | - | 24,483 | - | - | 4,940 | 19,543 | ||||||||||||||||
| Contingent consideration fair value adjustments(3) | - | (22,951) | - | 22,951 | - | - | 1,324 | 21,627 | ||||||||||||||||
| Executive transition costs(4) | - | (12,165) | - | 12,165 | - | - | 2,812 | 9,353 | ||||||||||||||||
| EU medical device regulations(5) | - | - | (785) | 785 | - | - | 11 | 774 | ||||||||||||||||
| Debt refinancing costs(6) | - | - | - | - | - | (418) | 47 | 371 | ||||||||||||||||
| Legal matters(7) | - | (2,609) | - | 2,609 | - | - | 454 | 2,155 | ||||||||||||||||
| Gain on sale of product line(8) | - | 354 | - | (354) | - | - | (82) | (272) | ||||||||||||||||
| Termination of distribution agreement(9) | (9,866) | - | - | (9,866) | - | - | (141) | (9,725) | ||||||||||||||||
| $ | 775,308 | $ | 539,438 | $ | 55,099 | $ | 180,771 | $ | 31,087 | $ | - | $ | 37,539 | $ | 112,145 | |||||||||
| Adjusted gross profit % | 56.4 | % | ||||||||||||||||||||||
| Amortization(10) | $ | 6,000 | (29,188) | - | 35,188 | (5,646) | - | 9,898 | 30,936 | |||||||||||||||
| As adjusted | $ | 510,250 | $ | 55,099 | $ | 215,959 | $ | 25,441 | $ | - | $ | 47,437 | 24.9 | % | $ | 143,081 | $ | 4.59 | ||||||
| % of sales | 37.1 | % | 4.0 | % | 15.7 | % | ||||||||||||||||||
| Year Ended December 31, 2024 | ||||||||||||||||||||||||
| Gross Profit | Selling & Administrative Expense | Research & Development Expense | Operating Income | Interest Expense | Other Expense | Tax Expense | Effective Tax Rate | Net Income | Diluted EPS | |||||||||||||||
| As reported | $ | 733,032 | $ | 478,280 | $ | 54,426 | $ | 200,326 | $ | 37,297 | $ | - | $ | 30,606 | 18.8 | % | $ | 132,423 | $ | 4.25 | ||||
| % of sales | 56.1 | % | 36.6 | % | 4.2 | % | 15.3 | % | ||||||||||||||||
| Legal matters(7) | - | (5,097) | - | 5,097 | - | - | 806 | 4,291 | ||||||||||||||||
| Restructuring and related costs(11) | 235 | (1,539) | - | 1,774 | - | - | 255 | 1,519 | ||||||||||||||||
| Product rationalization costs(2) | 1,414 | - | - | 1,414 | - | - | 203 | 1,211 | ||||||||||||||||
| Hurricane impact(12) | 955 | - | - | 955 | - | - | 829 | 126 | ||||||||||||||||
| Lease impairment(13) | - | (606) | - | 606 | - | - | 526 | 80 | ||||||||||||||||
| Termination of distributor agreement(14) | - | 970 | - | (970) | - | - | (139) | (831) | ||||||||||||||||
| Contingent consideration fair value adjustments(3) | - | 41,048 | - | (41,048) | - | - | (1,591) | (39,457) | ||||||||||||||||
| $ | 735,636 | $ | 513,056 | $ | 54,426 | $ | 168,154 | $ | 37,297 | $ | - | $ | 31,495 | $ | 99,362 | |||||||||
| Adjusted gross profit % | 56.3 | % | ||||||||||||||||||||||
| Amortization(10) | $ | 6,000 | (28,629) | - | 34,629 | (5,700) | - | 9,775 | 30,554 | |||||||||||||||
| As adjusted | $ | 484,427 | $ | 54,426 | $ | 202,783 | $ | 31,597 | $ | - | $ | 41,270 | 24.1 | % | $ | 129,916 | $ | 4.17 | ||||||
| % of sales | 37.1 | % | 4.2 | % | 15.5 | % | ||||||||||||||||||
| (1) In 2025, the Company incurred costs related to the engagement of a consulting firm to evaluate and propose improvements to our manufacturing operations which are included in cost of sales. In addition, we incurred consulting fees and other charges related to operational optimization which are included in selling & administrative expense. | ||||||||||||||||||||||||
| --- | ||||||||||||||||||||||||
| (2) In 2025, the Company wrote off inventory, equipment, tooling and patents to cost of goods sold related to the cancellation of planned new product lines and discontinuation of certain catalog numbers as a result of our operational optimization consultation and internal review. In addition, we wrote off the developed technology intangible asset to selling and administrative expense. In 2024, the Company wrote off inventory, tooling and equipment related to the cancellation of a planned new product line. | ||||||||||||||||||||||||
| (3) In 2025 and 2024, the Company recorded income/(expense) related to the fair value adjustments of contingent consideration. | ||||||||||||||||||||||||
| (4) In 2025, the Company incurred cash and stock-based compensation costs related to advisory services provided by our former Chief Executive Officer. | ||||||||||||||||||||||||
| (5) In 2025, the Company incurred costs to comply with the European Union's Medical Device Regulations (MDR). | ||||||||||||||||||||||||
| (6) In 2025, the Company incurred costs related to a loss on early extinguishment and third-party fees associated with the eighth amended and restated senior credit agreement. | ||||||||||||||||||||||||
| (7) In 2025 and 2024, the Company incurred costs for third party services pertaining to potential issues with certain royalty payments to design surgeons. | ||||||||||||||||||||||||
| (8) In 2025, the Company recognized a gain on the sale of a product line. | ||||||||||||||||||||||||
| (9) In 2025, the Company incurred income related to the early termination of an agreement granting the Company exclusive distribution rights. | ||||||||||||||||||||||||
| (10) Includes amortization of intangible assets and deferred financing fees. | ||||||||||||||||||||||||
| (11) In 2024, the Company incurred severance costs related to the elimination of certain positions. | ||||||||||||||||||||||||
| (12) In 2024, the Company incurred costs due to the impact of Hurricane Milton on our Largo, FL facility. These costs were mainly comprised of emergency pay to employees and plant underutilization due to abnormally low production. | ||||||||||||||||||||||||
| (13) In 2024, the Company recorded lease impairment expense related to a storage facility no longer utilized. | ||||||||||||||||||||||||
| (14) In 2024, the Company recorded an accrual adjustment related to the previous termination of a distributor agreement. | ||||||||||||||||||||||||
| Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA | ||||||||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ||||||||||||
| (in thousands, unaudited) | ||||||||||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||||||||||
| December 31, | December 31, | |||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||
| Net income | $ | 16,739 | $ | 33,754 | $ | 47,055 | $ | 132,423 | ||||||||||||||||
| Provision for income taxes | 12,514 | 9,888 | 24,062 | 30,606 | ||||||||||||||||||||
| Interest expense | 7,370 | 8,857 | 31,087 | 37,297 | ||||||||||||||||||||
| Depreciation | 4,066 | 4,199 | 17,143 | 16,605 | ||||||||||||||||||||
| Amortization | 14,784 | 13,807 | 57,138 | 55,252 | ||||||||||||||||||||
| EBITDA | $ | 55,473 | $ | 70,505 | $ | 176,485 | $ | 272,183 | ||||||||||||||||
| Stock-based compensation | 4,972 | 6,222 | 20,841 | 25,558 | ||||||||||||||||||||
| Contingent consideration fair value adjustments | 19,446 | 1,219 | 22,951 | (41,048) | ||||||||||||||||||||
| Product rationalization costs | 4,830 | - | 24,483 | 1,414 | ||||||||||||||||||||
| Operational optimization costs | 4,657 | - | 25,376 | - | ||||||||||||||||||||
| EU medical device regulations | 785 | - | 785 | - | ||||||||||||||||||||
| Legal matters | 60 | 531 | 2,609 | 5,097 | ||||||||||||||||||||
| Restructuring and related costs | - | - | - | 1,774 | ||||||||||||||||||||
| Executive transition costs | - | - | 12,165 | - | ||||||||||||||||||||
| Debt refinancing costs | - | - | 418 | - | ||||||||||||||||||||
| Gain on sale of product line | - | - | (354) | - | ||||||||||||||||||||
| Hurricane impact | - | 955 | - | 955 | ||||||||||||||||||||
| Lease impairment | - | 606 | - | 606 | ||||||||||||||||||||
| Termination of distribution agreement | (9,866) | - | (9,866) | - | ||||||||||||||||||||
| Termination of distributor agreement | - | - | - | (970) | ||||||||||||||||||||
| Adjusted EBITDA | $ | 80,357 | $ | 80,038 | $ | 275,893 | $ | 265,569 | ||||||||||||||||
| EBITDA Margin | ||||||||||||||||||||||||
| EBITDA | 14.9 | % | 20.4 | % | 12.8 | % | 20.8 | % | ||||||||||||||||
| Adjusted EBITDA | 21.5 | % | 23.1 | % | 20.1 | % | 20.3 | % |
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.
Forward-Looking Statements
This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures
The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted research and development expense; adjusted operating income; adjusted interest expense; adjusted other expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.
Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, research and development expense, operating income, interest expense, other expense, income tax expense, effective income tax rate, net income and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.